Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

NCT06253650 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
HER2-positive Gastric Cancer

Interventions

DRUG: Experimental
DRUG: Control

Sponsor

Gruppo Oncologico del Nord-Ovest